Karyopharm Therapeutics Inc. (KPTI) — Financial statements
Income statement, balance sheet, and cash flow for Karyopharm Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 146↑0.6% | 145↓0.5% | 146↓7.0% | 157↓25.1% | 210 | |
| Cost of Revenue | 6↓1.0% | 6↑21.5% | 5↓5.2% | 5↑53.2% | 3 | |
| Gross Profit | 140↑0.6% | 139↓1.3% | 141↓7.1% | 152↓26.4% | 206 | |
| Operating Expenses | ||||||
| R&D Expenses | 126↓12.3% | 143↑3.2% | 139↓6.7% | 149↓7.6% | 161 | |
| General & Administrative Expenses | 105↓8.9% | 115↓12.5% | 132↓9.3% | 145↑1.1% | 144 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 105↓8.9% | 115↓12.5% | 132↓9.3% | 145↑1.1% | 144 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 231↓10.8% | 259↓4.4% | 271↓8.0% | 294↓3.5% | 305 | |
| Total Costs & Expenses | 237↓10.5% | 265↓4.0% | 276↓7.9% | 299↓2.9% | 308 | |
| Operating Results | ||||||
| Operating Income | -91↑24.1% | -119↑7.8% | -130↑8.9% | -142↓44.7% | -98 | |
| Depreciation & Amortization | 0.30↓12.9% | 0.34↓35.8% | 0.53↓14.7% | 0.62↓21.3% | 0.79 | |
| EBITDA | -150↓288.2% | -39↑67.4% | -118↑15.0% | -139↓43.6% | -97 | |
| EBIT | -150↓285.6% | -39↑67.3% | -119↑15.0% | -140↓43.1% | -98 | |
| Interest & Other Income | ||||||
| Net Interest Income | -43↓43.5% | -30↓133.1% | -13↑43.1% | -23↑11.1% | -25 | |
| Interest Income | 3↓62.5% | 7↓32.4% | 11↑363.9% | 2↑305.3% | 0.58 | |
| Interest Expense | 46↑22.5% | 37↑57.1% | 24↓4.7% | 25↓4.0% | 26 | |
| Non-Operating Income | 59↑173.8% | -81↓660.4% | -11↓365.2% | -2↓357.9% | -0.50 | |
| Other Income / Expenses | -105↓344.4% | 43↑425.5% | -13↑41.7% | -23↑11.1% | -26 | |
| Income Before Tax | -196↓156.7% | -76↑46.5% | -143↑13.4% | -165↓33.2% | -124 | |
| Income Tax Expense | 0.04↓24.6% | 0.06↓82.4% | 0.32↓12.5% | 0.37↑37.7% | 0.27 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -196↓156.5% | -76↑46.6% | -143↑13.4% | -165↓33.2% | -124 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -196↓156.5% | -76↑46.6% | -143↑13.4% | -165↓33.2% | -124 | |
| Bottom-Line Net Income | -196↓156.5% | -76↑46.6% | -143↑13.4% | -165↓33.2% | -124 | |
| EPS (Basic) | -17.93↓90.5% | -9.41↑49.9% | -18.79↑37.9% | -30.28↓22.3% | -24.75 | |
| EPS (Diluted) | -17.93↓90.5% | -9.41↑49.9% | -18.79↑37.9% | -30.28↓22.3% | -24.75 | |
| Weighted Average Shares | 11↑34.6% | 8↑6.7% | 8↑39.5% | 5↑8.8% | 5 | |
| Weighted Average Diluted Shares | 11↑34.6% | 8↑6.7% | 8↑39.5% | 5↑8.8% | 5 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.